AIRNA Appoints Industry Veteran Todd Bazemore as President and CEO to Drive the Next Stage of Company Growth
AIRNA, a biotech company pioneering RNA-editing therapeutics to transform the lives of patients with rare and common conditions, today announced that Todd Bazemore has been appointed President and Chief Executive Officer as well as a member of the company’s Board of Directors. Mr. Bazemore is an accomplished biopharma executive with extensive leadership experience in clinical- and commercial-stage drug development.
AIRNA Presents New Preclinical Data on AATD Therapeutic Candidate AIR-001 and Cardiometabolic RNA-Editing Programs at ASGCT
AIRNA, a biotech company pioneering RNA-editing therapeutics to transform the lives of patients with rare and common conditions, is presenting new preclinical data on its therapeutic candidate AIR-001 for the treatment of alpha-1 antitrypsin deficiency (AATD) and its cardiometabolic RNA-editing research programs at the 2026 Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) in Boston from May 11-15, 2026. Together, the presentations demonstrate the potential of AIRNA’s RNA-editing platform both to repair disease-causing variants and to introduce protective variants associated with human health.
AIRNA to Present New Preclinical Data on RNA-Editing Therapeutic Pipeline at ASGCT Annual Meeting
AIRNA, a biotech company pioneering RNA-editing therapeutics to transform the lives of patients with rare and common conditions, will present new preclinical data from the company’s pipeline of RNA-editing therapeutics, including lead candidate AIR-001 and the company’s cardiometabolic portfolio, at the 2026 Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT).
AIRNA Announces First Patient Dosed in Phase 1 Trial of AIR-001, Potential Best-in-Class RNA-Editing Therapy for Alpha-1 Antitrypsin Deficiency (AATD)
AIRNA, a biotech company pioneering RNA-editing therapeutics to transform the lives of patients with rare and common conditions, today announced the first patient has been dosed in the global Phase 1 clinical trial of AIR-001, AIRNA’s potential best-in-class RNA-editing candidate for the treatment of alpha-1 antitrypsin deficiency (AATD).
AIRNA Appoints Allison Dorval as Chief Financial Officer and Niru Subramanian as Chief Operating Officer
AIRNA, a biotech company pioneering RNA editing therapeutics to transform the lives of patients with rare and common conditions, today announced the appointments of Allison Dorval as Chief Financial Officer (CFO) and Niru Subramanian as Chief Operating Officer (COO).
AIRNA Appoints Tamara Joseph as Chief Legal Officer and Kristina Storey as Head of Regulatory Affairs
AIRNA, a biotech company pioneering RNA editing therapeutics to transform the lives of patients with rare and common conditions, today announced the appointments of Tamara Joseph, J.D., L.L.M., as Chief Legal Officer (CLO) and Kristina Storey as Senior Vice President (SVP), Head of Regulatory Affairs.
AIRNA Presents Data Supporting RNA Editing Approach for Alpha-1 Antitrypsin Deficiency (AATD) at 28th ASGCT Annual Meeting
AIRNA, a biotech company pioneering RNA editing therapeutics to transform the lives of patients with rare and common conditions, today announced preclinical proof-of-concept data supporting its best-in-class RNA editing strategy for alpha-1 antitrypsin deficiency (AATD). These data are being presented May 14 from 5:30 – 7 PM CT during a poster session (#1106) at the 28th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) in New Orleans.
AIRNA Appoints Jacob Elkins Chief Medical Officer
AIRNA, a biotech company pioneering RNA editing therapeutics to transform the lives of patients with rare and common conditions, today announced the appointment of Jacob Elkins, M.D., as Chief Medical Officer. Dr. Elkins, an accomplished neurologist and biopharmaceutical executive, comes to AIRNA with two decades of leadership experience in translational and clinical drug development.
AIRNA Raises Oversubscribed $155 Million Series B Financing to Fund Phase 1/2 Clinical Trial for Alpha-1 Antitrypsin Deficiency and Future Pipeline
AIRNA, a biotech company pioneering RNA editing therapeutics to transform the lives of patients with rare and common conditions, today announced the closing of an oversubscribed $155 million Series B financing.
AIRNA Appoints Matthew Hawryluk as Chief Business Officer
AIRNA, a biotech company pioneering RNA editing therapeutics to restore the health of patients with rare and common diseases, today announced the appointment of Matthew Hawryluk, Ph.D., MBA, as Chief Business Officer. Dr. Hawryluk brings vast leadership experience in the life sciences sector, with a proven track record of bridging scientific innovation and commercial application.
AIRNA Raises Oversubscribed $60 Million Financing to Advance New Class of RNA Editing Medicines and Progress Best-in-Class AATD Program into the Clinic
AIRNA, a biotech company pioneering RNA editing therapeutics to restore the health of patients with rare and common diseases, today announced the successful closing of an oversubscribed $60 million financing round, which brings the total Series A funding to $90 million.
AIRNA Launches to Develop New Class of RNA Editing Therapeutics for Rare and Common Diseases
AIRNA, a biotech company pioneering RNA editing therapeutics to restore the health of patients with rare and common diseases, today emerged from stealth with a $30 million initial financing led by ARCH Venture Partners. The financing enables AIRNA’s experienced team to advance a pipeline of RNA editing therapeutics driven by its powerful and flexible RNA editing platform, RESTORE+TM.
